+44-1518081136Weekly cabazitaxel in elderly patients (EP) with metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel treatment: WeCabE, a phase II study
Clinical Trials and Pharmacovigilance
September 23-24, 2019 | Prague, Czech Republic
A Bruno Castagneto and B Ilaria Stevani
Ospedale San Giacomo, Italy
Posters & Accepted Abstracts : J Clin Res Pharm
Abstract:
Background: Cabazitaxel (Cab) every 3 weeks with daily
prednisone is considered a possible option as second line
chemotherapy in mCRPC. According to SIOG guidelines the
G8 Screening Tool might be useful to detect unfit EP.
Methods: EP with mCRPC, ≥ 70 and < 85 years, G8 Score 8-14
which identify unfit patients (i.e. no frail, no fit), PS 0-2 were
enrolled.
Cab was administered at a dose of 8mg /m2 for 4 out 5 weeks.
Primary end point was PFS. Secondary endpoints were: PSA
Response, ORR, OS, Safety, impact on Geriatric assessment
according with Elderly Task Force EORTC.
Results: At time of this analysis 14 EP were analysed. Median
age was 78 years, 35.7% of pts were 80-85 years. Median
number of cycles received, in pts who ended treatment was
4. Overall 55.6% of pts reached a PSA response while 33.3%
achieved a stability. 42.8% of pts ended therapy without a
worsening/rising of symptoms.
G8 best score improvement during treatment was 1.28
(median). The most common AE G 3-4 was fatigue (20%)
while G1-2 toxicities were diarrhea (40%) and fatigue (60%).
Only one pt experienced neutropenia and anemia G3-4.
Conclusions: These preliminary results confirm the usefulness
of G8 tool to identify elderly mCRPC pts suitable to receive
chemotherapy. It suggests that weekly cab in mCRPC EP
(including very old pts > 80 ), is effective, with a manageable
safety profile.
Biography:
E-mail:
bruno.castagneto@gmail.comPDF HTML